These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 23166310

  • 1. COSMOS: the dialysis scenario of CKD-MBD in Europe.
    Fernández-Martín JL, Carrero JJ, Benedik M, Bos WJ, Covic A, Ferreira A, Floege J, Goldsmith D, Gorriz JL, Ketteler M, Kramar R, Locatelli F, London G, Martin PY, Memmos D, Nagy J, Naves-Díaz M, Pavlovic D, Rodríguez-García M, Rutkowski B, Teplan V, Tielemans C, Verbeelen D, Wüthrich RP, Martínez-Camblor P, Cabezas-Rodriguez I, Sánchez-Alvarez JE, Cannata-Andia JB.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1922-35. PubMed ID: 23166310
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
    Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, Floege J, Ketteler M, London G, Locatelli F, Gorriz JL, Rutkowski B, Ferreira A, Bos WJ, Covic A, Rodríguez-García M, Sánchez JE, Rodríguez-Puyol D, Cannata-Andia JB, COSMOS group.
    Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921
    [Abstract] [Full Text] [Related]

  • 4. Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS).
    Cannata-Andía JB, Fernández-Martín JL, Zoccali C, London GM, Locatelli F, Ketteler M, Ferreira A, Covic A, Floege J, Górriz JL, Rutkowski B, Memmos DE, Verbeelen D, Tielemans C, Teplan V, Bos WJ, Nagy J, Kramar R, Goldsmith DJ, Martin PY, Wüthrich RP, Pavlovic D, Benedik M.
    J Nephrol; 2008 Sep; 21(3):290-8. PubMed ID: 18587716
    [Abstract] [Full Text] [Related]

  • 5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 6. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E.
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [Abstract] [Full Text] [Related]

  • 7. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease.
    Reichel H.
    Nephron Clin Pract; 2010 Apr; 114(4):c268-76. PubMed ID: 20090369
    [Abstract] [Full Text] [Related]

  • 8. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study.
    Neri L, Kreuzberg U, Bellocchio F, Brancaccio D, Barbieri C, Canaud B, Stuard S, Ketteler M.
    Nephrol Dial Transplant; 2019 Apr 01; 34(4):682-691. PubMed ID: 30165528
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of whole PTH assay and 1-84/non-(1-84) PTH ratio in patients on hemodialysis or undergoing parathyroidectomy.
    Kato Y, Yamaguchi S, Yachiku S, Fujisawa M, Kawakami N.
    Hinyokika Kiyo; 2004 Nov 01; 50(11):755-62. PubMed ID: 15628534
    [Abstract] [Full Text] [Related]

  • 10. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R.
    J Nephrol; 2016 Feb 01; 29(1):71-8. PubMed ID: 25986389
    [Abstract] [Full Text] [Related]

  • 11. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study.
    Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Saha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D.
    Nephrol Dial Transplant; 2009 Sep 01; 24(9):2852-9. PubMed ID: 19369690
    [Abstract] [Full Text] [Related]

  • 12. Achievement of NKF/K-DOQI recommended target values for bone and mineral metabolism in incident hemodialysis patients: results of the FARO-2 cohort.
    Cozzolino M, Messa P, Brancaccio D, Cannella G, Bolasco P, Di Luca M, Costanzo AM, Paparatti Ud, Festa V, Gualberti G, Mazzaferro S, FARO Study Group.
    Blood Purif; 2014 Sep 01; 38(1):37-45. PubMed ID: 25277167
    [Abstract] [Full Text] [Related]

  • 13. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?
    Ghazali A, Fardellone P, Pruna A, Atik A, Achard JM, Oprisiu R, Brazier M, Remond A, Morinière P, Garabedian M, Eastwood J, Fournier A.
    Kidney Int; 1999 Jun 01; 55(6):2169-77. PubMed ID: 10354266
    [Abstract] [Full Text] [Related]

  • 14. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
    Koiwa F, Maruta Y.
    Clin Calcium; 2010 Jul 01; 20(7):1089-95. PubMed ID: 20585188
    [Abstract] [Full Text] [Related]

  • 15. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
    Cozzolino M, Brancaccio D, Cannella G, Messa P, Gesualdo L, Marangella M, LoDeserto C, Pozzato M, Rombolà G, Costanzo AM, di Luzio Paparatti U, Mazzaferro S, FARO Study Group.
    Nephrol Dial Transplant; 2012 Sep 01; 27(9):3588-94. PubMed ID: 22523119
    [Abstract] [Full Text] [Related]

  • 16. Characteristics of bone mineral metabolism in patients with stage 3-5 chronic kidney disease not on dialysis: results of the OSERCE study.
    Górriz JL, Molina P, Bover J, Barril G, Martín-de Francisco AL, Caravaca F, Hervás J, Piñera C, Escudero V, Molinero LM, en nombre de los investigadores del estudio OSERCE.
    Nefrologia; 2013 Jan 18; 33(1):46-60. PubMed ID: 23364626
    [Abstract] [Full Text] [Related]

  • 17. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C, González EA, Martin KJ.
    Ther Apher Dial; 2005 Feb 18; 9(1):4-8. PubMed ID: 15828898
    [Abstract] [Full Text] [Related]

  • 18. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.
    Barrera-Baena P, Rodríguez-García M, Rodríguez-Rubio E, González-Llorente L, Ortiz A, Zoccali C, Locatelli F, Floege J, Cohen-Solal M, Ferreira MA, Ketteler M, London GM, Gorriz-Teruel JL, Sánchez-Álvarez E, Hevia-Suárez MÁ, Fernández-Gómez JM, Martín-Carro B, Gómez-Alonso C, Alonso-Montes C, Cannata-Andía JB, Fernández-Martín JL, COSMOS .
    Nephrol Dial Transplant; 2024 Mar 27; 39(4):618-626. PubMed ID: 37660283
    [Abstract] [Full Text] [Related]

  • 19. Secondary hyperparathyroidism: review of the disease and its treatment.
    de Francisco AL.
    Clin Ther; 2004 Dec 27; 26(12):1976-93. PubMed ID: 15823762
    [Abstract] [Full Text] [Related]

  • 20. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.
    Zisman AL, Hristova M, Ho LT, Sprague SM.
    Am J Nephrol; 2007 Dec 27; 27(1):36-43. PubMed ID: 17215573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.